Bluejay Diagnostics logo

Bluejay DiagnosticsNASDAQ: BJDX

Profile

Sector:

Healthcare

Country:

United States

IPO:

10 November 2021

Next earnings report:

15 May 2025

Last dividends:

N/A

Next dividends:

N/A
$1.78 M
-10%vs. 3y high
4%vs. sector
-vs. 3y high
-vs. sector
-10%vs. 3y high
20%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:05:09 GMT
$3.31-$0.28(-7.80%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

BJDX Latest News

Bluejay Diagnostics Announces Reverse Stock Split
globenewswire.com13 November 2024 Sentiment: NEUTRAL

ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, “BJDX.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633509.

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
globenewswire.com28 June 2024 Sentiment: POSITIVE

ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
globenewswire.com26 June 2024 Sentiment: POSITIVE

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).

Why Is Bluejay Diagnostics (BJDX) Stock Up 17% Today?
InvestorPlace07 July 2023 Sentiment: POSITIVE

Bluejay Diagnostics (NASDAQ: BJDX ) stock is rising higher on Friday despite a lack of news from the medical diagnostic company. There have been no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is rallying this morning.

What type of business is Bluejay Diagnostics?

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

What sector is Bluejay Diagnostics in?

Bluejay Diagnostics is in the Healthcare sector

What industry is Bluejay Diagnostics in?

Bluejay Diagnostics is in the Medical Devices industry

What country is Bluejay Diagnostics from?

Bluejay Diagnostics is headquartered in United States

When did Bluejay Diagnostics go public?

Bluejay Diagnostics initial public offering (IPO) was on 10 November 2021

What is Bluejay Diagnostics website?

https://bluejaydx.com

Is Bluejay Diagnostics in the S&P 500?

No, Bluejay Diagnostics is not included in the S&P 500 index

Is Bluejay Diagnostics in the NASDAQ 100?

No, Bluejay Diagnostics is not included in the NASDAQ 100 index

Is Bluejay Diagnostics in the Dow Jones?

No, Bluejay Diagnostics is not included in the Dow Jones index

When was Bluejay Diagnostics the previous earnings report?

No data

When does Bluejay Diagnostics earnings report?

The next expected earnings date for Bluejay Diagnostics is 15 May 2025